Research
Hormonal
MC3R inhibition generalizes to enhance sensitivity to other anorectic hormones, including leptin, peptide YY (PYY3-36), and cholecystokinin (CCK).
Blocking the MC3R receptor doesn't just help GLP-1 drugs; it may also make your body's natural satiety signals (like leptin and gut hormones) work more effectively. This suggests a broader benefit for appetite control beyond just one drug class.
GoodSupportsHIGH confidence
An enhanced anorectic response to other agents, including the acute satiety factors peptide YY (PYY3-36) and cholecystokinin (CCK) and the long-term adipostatic factor, leptin, demonstrated that increased sensitivity to anorectic agents is a generalized result of MC3R antagonism.
Why this rating
Consistent preclinical findings across multiple hormones, but limited to animal models.
Source
Inhibition of the melanocortin-3 receptor (MC3R) causes generalized sensitization to anorectic agents
Naima S. Dahir et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2023
DOI 10.1101/2023.12.05.570114
preprintCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →